Takayoshi Suzuki

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8349131/publications.pdf

Version: 2024-02-01

113 papers	4,405 citations	94269 37 h-index	118652 62 g-index
121 all docs	121 docs citations	121 times ranked	5050 citing authors

#	Article	IF	Citations
1	KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer. Cancer Letters, 2022, 524, 219-231.	3.2	12
2	Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC). Chemical Communications, 2022, 58, 4635-4638.	2.2	25
3	Using Î±- and Î²-Epimerizations of cis-2,3-Bis(hydroxymethyl)-Î³-butyrolactone for the Synthesis of Both Enantiomers of Enterolactone. Journal of Organic Chemistry, 2022, , .	1.7	2
4	Recent progress on small molecules targeting epigenetic complexes. Current Opinion in Chemical Biology, 2022, 67, 102130.	2.8	6
5	Medicinal Chemistry Research on Targeting Epigenetic Complexes. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2022, 80, 664-675.	0.0	0
6	KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer. Breast Cancer Research and Treatment, 2021, 185, 343-357.	1.1	20
7	Celiac Disease Complicated by Rhabdomyolysis. Internal Medicine, 2021, 60, 217-222.	0.3	2
8	Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5â€…C Degraders. ChemMedChem, 2021, 16, 1609-1618.	1.6	14
9	Synthetic RNA Modulators in Drug Discovery. Journal of Medicinal Chemistry, 2021, 64, 7110-7155.	2.9	10
10	Simplifying Submission Requirements for the Journal of Medicinal Chemistry. Journal of Medicinal Chemistry, 2021, 64, 7877-7878.	2.9	0
11	Identification of Novel Histone Deacetylase 6â€Selective Inhibitors Bearing 3,3,3â€Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group. ChemBioChem, 2021, 22, 3158-3163.	1.3	4
12	Three Cases of Esophageal Cancer Related to Fanconi Anemia. Internal Medicine, 2021, 60, 2953-2959.	0.3	2
13	Catalytic enantioselective intramolecular Tishchenko reaction of meso-dialdehyde: synthesis of (S)-cedarmycins. RSC Advances, 2021, 11, 11606-11609.	1.7	6
14	Identification of Potent and Selective Inhibitors of Fat Mass Obesity-Associated Protein Using a Fragment-Merging Approach. Journal of Medicinal Chemistry, 2021, 64, 15810-15824.	2.9	19
15	Early sirtuin 2 inhibition prevents age-related cognitive decline in a senescence-accelerated mouse model. Neuropsychopharmacology, 2020, 45, 347-357.	2.8	35
16	Discovery of gamma-mangostin from Garcinia mangostana as a potent and selective natural SIRT2 inhibitor. Bioorganic Chemistry, 2020, 94, 103403.	2.0	21
17	LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia. Leukemia, 2020, 34, 746-758.	3.3	23
18	Metabolic-Pathway-Oriented Screening Targeting S-Adenosyl-l-methionine Reveals the Epigenetic Remodeling Activities of Naturally Occurring Catechols. Journal of the American Chemical Society, 2020, 142, 21-26.	6.6	10

#	Article	IF	Citations
19	Possible Contribution of Inflammation-Associated Hypoxia to Increased K2P5.1 K+ Channel Expression in CD4+ T Cells of the Mouse Model for Inflammatory Bowel Disease. International Journal of Molecular Sciences, 2020, 21, 38.	1.8	6
20	Excellence in Medicinal Chemistry Research from Japan. Journal of Medicinal Chemistry, 2020, 63, 8877-8879.	2.9	0
21	Downregulation of the Ca²⁺-activated K⁺ channel K_{Ca}3.1 in mouse preosteoblast cells treated with vitamin D receptor agonist. American Journal of Physiology - Cell Physiology, 2020, 319, C345-C358.	2.1	9
22	Selective lysineâ€specific demethylase 1 inhibitor, NCL1, could cause testicular toxicity via the regulation of apoptosis. Andrology, 2020, 8, 1895-1906.	1.9	2
23	Metalloprotein-Catalyzed Click Reaction for In Situ Generation of a Potent Inhibitor. ACS Catalysis, 2020, 10, 5383-5392.	5.5	13
24	Epigenetic Control Using Small Molecules in Cancer. Human Perspectives in Health Sciences and Technology, 2020, , 111-148.	0.2	2
25	Genomeâ€wide ChIPâ€seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells. Oncology Letters, 2019, 18, 872-881.	0.8	8
26	N+-C-HÂ·Â·Â·O Hydrogen bonds in protein-ligand complexes. Scientific Reports, 2019, 9, 767.	1.6	81
27	Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the â€œSelectivity Pocketâ€ Substrate-Binding Site, and NAD⁺-Binding Site. Journal of Medicinal Chemistry, 2019, 62, 5844-5862.	2.9	16
28	Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity. Pathology International, 2019, 69, 260-271.	0.6	10
29	Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1173-1176.	1.0	5
30	NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy. Journal of Clinical Medicine, 2019, 8, 442.	1.0	19
31	Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy. Bioorganic and Medicinal Chemistry, 2019, 27, 1119-1129.	1.4	26
32	Discovery of Second Generation RORÎ³ Inhibitors Composed of an Azole Scaffold. Journal of Medicinal Chemistry, 2019, 62, 2837-2842.	2.9	24
33	Lysine-Specific Histone Demethylases 1/2 (LSD1/2) and Their Inhibitors. Topics in Medicinal Chemistry, 2019, , 197-219.	0.4	1
34	HDAC8 inhibition ameliorates pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L175-L186.	1.3	43
35	Design, Synthesis, and Biological Evaluation of a Conjugate of 5-Fluorouracil and an LSD1 Inhibitor. Chemical and Pharmaceutical Bulletin, 2019, 67, 192-195.	0.6	6
36	Computational analysis for selectivity of histone deacetylase inhibitor by replica-exchange umbrella sampling molecular dynamics simulations. Journal of Chemical Physics, 2018, 148, 125102.	1.2	7

#	Article	IF	Citations
37	Design, synthesis and evaluation of Î³-turn mimetics as LSD1-selective inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 775-785.	1.4	17
38	HDAC8 regulates neural differentiation through embryoid body formation in P19â€¯cells. Biochemical and Biophysical Research Communications, 2018, 498, 45-51.	1.0	25
39	Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 167-169.	1.0	12
40	Histone Deacetylases Enhance Ca2+-Activated K+ Channel KCa3.1 Expression in Murine Inflammatory CD4+ T Cells. International Journal of Molecular Sciences, 2018, 19, 2942.	1.8	18
41	Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants. Journal of Medicinal Chemistry, 2018, 61, 10000-10016.	2.9	81
42	Drug Design Concepts for LSD1â€Selective Inhibitors. Chemical Record, 2018, 18, 1782-1791.	2.9	14
43	Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating Î±,Î±-Disubstituted Amino Acids with Î³-Turn-Inducing Structures. Molecules, 2018, 23, 1099.	1.7	9
44	Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines. BMC Cancer, 2018, 18, 791.	1.1	41
45	Selective dissociation between LSD1 and GFI1B by a LSD1 inhibitor NCD38 induces the activation ofERGsuper-enhancer in erythroleukemia cells. Oncotarget, 2018, 9, 21007-21021.	0.8	24
46	Region-specific alteration of histone modification by LSD1 inhibitor conjugated with pyrrole-imidazole polyamide. Oncotarget, 2018, 9, 29316-29335.	0.8	6
47	CRTC1 Nuclear Translocation Following Learning Modulates Memory Strength via Exchange of Chromatin Remodeling Complexes on the Fgf1 Gene. Cell Reports, 2017, 18, 352-366.	2.9	49
48	SIRT2 inhibition modulate glutamate and serotonin systems in the prefrontal cortex and induces antidepressant-like action. Neuropharmacology, 2017, 117, 195-208.	2.0	50
49	Transcriptional repression of HER2 by ANO1 Clâ¯ channel inhibition in human breast cancer cells with resistance to trastuzumab. Biochemical and Biophysical Research Communications, 2017, 482, 188-194.	1.0	19
50	DNA and Histone Modifications in Cancer Therapy. Cancer Drug Discovery and Development, 2017, , 585-604.	0.2	0
51	Potent mechanism-based sirtuin-2-selective inhibition by an in situ-generated occupant of the substrate-binding site, â€œselectivity pocketâ€•and NAD⁺-binding site. Chemical Science, 2017, 8, 6400-6408.	3.7	56
52	ADrosophilaModel for Screening Antiobesity Agents. BioMed Research International, 2016, 2016, 1-10.	0.9	12
53	Down-Regulation of Ca2+-Activated K+ Channel KCa1.1 in Human Breast Cancer MDA-MB-453 Cells Treated with Vitamin D Receptor Agonists. International Journal of Molecular Sciences, 2016, 17, 2083.	1.8	15
54	Hippocampal MicroRNA-124 Enhances Chronic Stress Resilience in Mice. Journal of Neuroscience, 2016, 36, 7253-7267.	1.7	130

#	Article	IF	Citations
55	Downregulation of the Ca²⁺â€activated K⁺ channel <scp>K_C</scp>_a3.1 by histone deacetylase inhibition in human breast cancer cells. Pharmacology Research and Perspectives, 2016, 4, e00228.	1.1	15
56	Câ€“H activation enables a rapid structureâ€“activity relationship study of arylcyclopropyl amines for potent and selective LSD1 inhibitors. Organic and Biomolecular Chemistry, 2016, 14, 8576-8585.	1.5	30
57	Targeting Cancer with PCPAâ€Drug Conjugates: LSD1 Inhibitionâ€Triggered Release of 4â€Hydroxytamoxifen. Angewandte Chemie, 2016, 128, 16349-16352.	1.6	4
58	Targeting Cancer with PCPAâ€Drug Conjugates: LSD1 Inhibitionâ€Triggered Release of 4â€Hydroxytamoxifen. Angewandte Chemie - International Edition, 2016, 55, 16115-16118.	7.2	31
59	False HDAC Inhibition by Aurone Compound. Chemical and Pharmaceutical Bulletin, 2016, 64, 1124-1128.	0.6	11
60	Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structureâ€“activity relationship analysis. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2284-2288.	1.0	19
61	Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1193-1195.	1.0	8
62	Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators. Journal of Medicinal Chemistry, 2016, 59, 1531-1544.	2.9	30
63	Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells. Annals of Surgical Oncology, 2016, 23, 312-320.	0.7	25
64	Molecular Technology for Controlling Epigenetics: Regulation of Histone Acetylation and Methylation by Small Molecules. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2016, 74, 441-452.	0.0	1
65	Peptidyl prolyl isomerase Pin1-inhibitory activity of d -glutamic and d -aspartic acid derivatives bearing a cyclic aliphatic amine moiety. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5619-5624.	1.0	10
66	Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells. ACS Medicinal Chemistry Letters, 2015, 6, 665-670.	1.3	46
67	Medicinal chemistry insights in the discovery of novel LSD1 inhibitors. Epigenomics, 2015, 7, 1379-1396.	1.0	42
68	Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators. Journal of Medicinal Chemistry, 2015, 58, 7611-7633.	2.9	49
69	Novel small-molecule SIRT1 inhibitors induce cell death in adult T-cell leukaemia cells. Scientific Reports, 2015, 5, 11345.	1.6	33
70	A double bond-conjugated dimethylnitrobenzene-type photolabile nitric oxide donor with improved two-photon cross section. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3172-3175.	1.0	11
71	Histone H3 peptide based LSD1-selective inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1925-1928.	1.0	30
72	Design, synthesis, and biological activity of N-alkylated analogue of NCL1, a selective inhibitor of lysine-specific demethylase 1. MedChemComm, 2015, 6, 407-412.	3.5	26

#	Article	IF	Citations
73	Enrichment of O-GlcNAc-modified peptides using novel thiol-alkyne and thiol-disulfide exchange. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2645-2649.	1.0	5
74	Stereodivergent Synthesis of Arylcyclopropylamines by Sequential Cï£¿H Borylation and Suzukiâ€“Miyaura Coupling. Angewandte Chemie - International Edition, 2015, 54, 846-851.	7.2	79
75	NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect. Oncotarget, 2015, 6, 2865-2878.	0.8	44
76	Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. American Journal of Cancer Research, 2015, 5, 1519-30.	1.4	30
77	Histone Deacetylase Inhibitor Valproic Acid Promotes the Differentiation of Human Induced Pluripotent Stem Cells into Hepatocyte-Like Cells. PLoS ONE, 2014, 9, e104010.	1.1	31
78	Anticancer Agents Targeted to Sirtuins. Molecules, 2014, 19, 20295-20313.	1.7	54
79	Visible light-induced nitric oxide release from a novel nitrobenzene derivative cross-conjugated with a coumarin fluorophore. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5660-5662.	1.0	25
80	Downregulation of Ca²⁺-Activated Cl^{â^'} Channel TMEM16A by the Inhibition of Histone Deacetylase in TMEM16A-Expressing Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 510-518.	1.3	37
81	Design, Synthesis, and Biological Activity of NCC149 Derivatives as Histone Deacetylaseâ€…8â€Selective Inhibitors. ChemMedChem, 2014, 9, 657-664.	1.6	59
82	Late-Stage Câ€“H Coupling Enables Rapid Identification of HDAC Inhibitors: Synthesis and Evaluation of NCH-31 Analogues. ACS Medicinal Chemistry Letters, 2014, 5, 582-586.	1.3	23
83	Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2). Bioscience, Biotechnology and Biochemistry, 2014, 78, 1010-1017.	0.6	11
84	SYNTHESIS, LSD1 INHIBITORY ACTIVITY, AND LSD1 BINDING MODEL OF OPTICALLY PURE LYSINE-PCPA CONJUGATES. Computational and Structural Biotechnology Journal, 2014, 9, e201402002.	1.9	17
85	Identification of novel SIRT2-selective inhibitors using a click chemistry approach. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1871-1874.	1.0	38
86	Differential Effect of HDAC3 on Cytoplasmic and Nuclear Huntingtin Aggregates. PLoS ONE, 2014, 9, e111277.	1.1	18
87	The Pharmacological Inhibition of KDM1A Displays Preclinical Efficacy in AML and MDS By Inducing Myelomonocytic Differentiation. Blood, 2014, 124, 1010-1010.	0.6	5
88	Small-molecular modulators of cancer-associated epigenetic mechanisms. Molecular BioSystems, 2013, 9, 873.	2.9	42
89	Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and its Antiproliferative Activity. Journal of Medicinal Chemistry, 2013, 56, 7222-7231.	2.9	77
90	An Overview of Phenylcyclopropylamine Derivatives: Biochemical and Biological Significance and Recent Developments. Medicinal Research Reviews, 2013, 33, 873-910.	5.0	30

#	Article	IF	Citations
91	Lysineâ€Specific Demethylase 1â€Selective Inactivators: Proteinâ€Targeted Drug Delivery Mechanism. Angewandte Chemie - International Edition, 2013, 52, 8620-8624.	7.2	69
92	Identification of Highly Selective and Potent Histone Deacetylase 3 Inhibitors Using Click Chemistry-Based Combinatorial Fragment Assembly. PLoS ONE, 2013, 8, e68669.	1.1	79
93	Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries. Journal of Medicinal Chemistry, 2012, 55, 9562-9575.	2.9	135
94	Design, Synthesis, and Biological Activity of a Novel Series of Human Sirtuin-2-Selective Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 5760-5773.	2.9	115
95	Epigenetic Status of Gdnf in the Ventral Striatum Determines Susceptibility and Adaptation to Daily Stressful Events. Neuron, 2011, 69, 359-372.	3.8	345
96	Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Letters, 2011, 585, 1103-1111.	1.3	28
97	Lysine Demethylases Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 8236-8250.	2.9	140
98	Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. Bioorganic and Medicinal Chemistry, 2011, 19, 3702-3708.	1.4	50
99	Design, Synthesis, Enzyme-Inhibitory Activity, and Effect on Human Cancer Cells of a Novel Series of Jumonji Domain-Containing Protein 2 Histone Demethylase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 5629-5638.	2.9	156
100	An Unexpected Example of Proteinâ€Templated Click Chemistry. Angewandte Chemie - International Edition, 2010, 49, 6817-6820.	7.2	68
101	Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 5900-5905.	1.4	37
102	Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2852-2855.	1.0	116
103	Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5670-5672.	1.0	50
104	Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 2909-2922.	2.9	70
105	Identification of Cell-Active Lysine Specific Demethylase 1-Selective Inhibitors. Journal of the American Chemical Society, 2009, 131, 17536-17537.	6.6	182
106	Isoform-Selective Histone Deacetylase Inhibitors. Current Pharmaceutical Design, 2008, 14, 529-544.	0.9	105
107	Design, Synthesis, Structureâ^'Selectivity Relationship, and Effect on Human Cancer Cells of a Novel Series of Histone Deacetylase 6-Selective Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 5425-5438.	2.9	98
108	Highly Potent and Selective Histone Deacetylase 6 Inhibitors Designed Based on a Small-Molecular Substrate. Journal of Medicinal Chemistry, 2006, 49, 4809-4812.	2.9	109

#	Article	IF	Citations
109	2-Anilinobenzamides as SIRT Inhibitors. ChemMedChem, 2006, 1, 1059-1062.	1.6	58
110	Epigenetic Control Using Natural Products and Synthetic Molecules. Current Medicinal Chemistry, 2006, 13, 935-958.	1.2	70
111	Novel Inhibitors of Human Histone Deacetylases:Â Design, Synthesis, Enzyme Inhibition, and Cancer Cell Growth Inhibition of SAHA-Based Non-hydroxamates. Journal of Medicinal Chemistry, 2005, 48, 1019-1032.	2.9	109
112	Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-Based non-hydroxamates. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4321-4326.	1.0	41
113	Anaphylactoid purpura with intestinal perforation: Report of a case and review of the Japanese literature. Pathology International, 1994, 44, 303-308.	0.6	13